EFFECTS OF THE SEROTONIN(2) RECEPTOR AGONIST DOI ON SKELETAL-MUSCLE SPECIMENS FROM MALIGNANT HYPERTHERMIA-SUSCEPTIBLE PATIENTS

Background: Administration of serotonin(2) (5-HT2) receptor agonists i n pigs triggers malignant hyperthermia (MH) and psychotic-like behavio r. Both can be reduced by 5-HT2, receptor antagonists. Furthermore, an increase in the plasma concentration of 5-HT has been found during on set of halothane-Induced MH in pigs. Therefore, In this study, the in vitro effects of the 5-HT2 receptor agonist 1-(2,5-dimethoxy-4-Iodophe nyl)-2-aminopropane (DOI) were investigated in muscle specimens from,M A-susceptible (MHS) and -negative (MHN) patients. Methods: lifter MH c lassification using the caffeine-halothane contracture test (CHCT), su rplus muscle specimens from 23 MHS and 17 MAN patients were used to ex amine the effects of DOI. In the first study, DOI was added to the bat h in a concentration of 0.02 mM. In a second experiment, muscles were preincubated for 60 min with 0.02 mM DOI, and subsequently, halothane was added incrementally to the organ bath (0.11-0.22-0.44 mM) for IS m in according to the CHCT protocol. The in vitro effects of DOI on cont racture development and muscle twitch were measured for 120 min In bot h investigations. Results: Muscle specimens from all patients develope d contractures after administration of DOI, characterized by a signifi cantly earlier development of contracture in MHS (16.8 +/- 1.7 min) th an in MHN (66.3 +/- 5.8 min) muscles (P < 0.05). There was no overlap between the groups In the range of times. The onset of contracture dev elopment after DOI was prolonged by halothane in specimens from MHN pa tients (89.7 +/- 5.6 min) but not MHS patients. Preincubation with DOI increased the halothane-lnduced contractures in specimens from MHS pa tients compared to the results of the CHCT. The contracture developmen t In specimens from MHS patients was larger than from MHN patients. At the end of the experiment, contractures had reached a maximum of 12.9 +/- 1.1 mN in specimens from MHS and 5.3 +/- 0.6 mN in MHN patients ( P < 0.05). The additional administration of halothane led to significa ntly increased contractures in specimens from MAS individuals (15.9 +/ - 0.9 mN) at 120 min. However, the contracture development decreased s ignificantly to 3.1 +/- 0.4 mN in MHN muscles. Muscle twitch after DOI administration was reduced significantly in specimens from MHS and MH N patients. Conclusions: A functional or structural altered serotonin system might be involved in the development of MH in humans.